VALN(VALN)
VALN
ANALYST COVERAGE2 analysts
BUY
▲ +86.8%upside to target
Key MetricsTTM
Market Cap$478.10M
Revenue TTM$156.33M
Net Income TTM-$138.03M
Free Cash Flow-$70.92M
Gross Margin29.5%
Operating Margin-68.8%
Net Margin-88.3%
Return on Equity-106.2%
Return on Assets-37.1%
Debt / Equity2.73
Current Ratio2.14
EPS TTM$-0.80
PRICE
Prev Close
5.87
Open
5.87
Day Range5.76 – 5.90
5.76
5.90
52W Range5.06 – 12.25
5.06
12.25
12% of range
VOLUME & SIZE
Avg Volume
90.1K
FUNDAMENTALS
P/E Ratio
-3.2x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.31
Market-like
TECHNICAL
RSI (14)
30
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 23
DEx-Dividend
In 90 days
Aug 20
PDividend Pay
In 119 days
Sep 18
VALN News
About
Valneva SE is a French biotech company headquartered in Saint-Herblain, France, developing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden and Vienna, Austria, with other offices in France, Canada and the United States.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Thomas Lingelbach
Country
France
Website
Hanneke SchuitemakerChief Scientific Officer
Juan-Carlos JaramilloChief Medical Officer
Petra PesendorferChief People Officer
Joshua DrummVice President of Investor Relations
Peter BuhlerChief Financial Officer
Thomas LingelbachPresident, Chief Executive Officer & Director
Vincent DequenneChief Operating Officer
Dipal PatelChief Commercial Officer
Kendra WerginGeneral Counsel & Corporate Secretary
Laetitia Bachelot-FontaineVice President of Global Communications & European Investor Relations